| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/22/2023 | 177.78% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 177.78% | Cantor Fitzgerald | → $4 | Reiterates | Overweight → Overweight |
| 08/16/2023 | 94.44% | Needham | → $2.8 | Reiterates | Buy → Buy |
| 05/17/2023 | 177.78% | Cantor Fitzgerald | $4.5 → $4 | Maintains | Overweight |
| 05/17/2023 | 94.44% | Needham | $2.6 → $2.8 | Maintains | Buy |
| 04/21/2023 | 80.56% | Needham | → $2.6 | Reiterates | → Buy |
| 03/14/2023 | 80.56% | Needham | $3.1 → $2.6 | Maintains | Buy |
| 11/18/2022 | 143.06% | BTIG | $5 → $3.5 | Maintains | Buy |
| 11/15/2022 | 115.28% | Needham | $4.25 → $3.1 | Maintains | Buy |
| 08/16/2022 | 195.14% | Needham | $5 → $4.25 | Maintains | Buy |
| 05/12/2022 | 247.22% | Needham | $7 → $5 | Maintains | Buy |
| 03/29/2022 | 733.33% | Canaccord Genuity | $18 → $12 | Maintains | Buy |
| 03/29/2022 | 386.11% | Needham | $13 → $7 | Maintains | Buy |
| 12/27/2021 | 1011.11% | Ascendiant Capital | → $16 | Initiates Coverage On | → Buy |
| 12/15/2021 | 802.78% | Needham | $17 → $13 | Maintains | Buy |
| 11/08/2021 | 872.22% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1150% | Canaccord Genuity | → $18 | Initiates Coverage On | → Buy |
| 11/08/2021 | 1358.33% | Cantor Fitzgerald | → $21 | Initiates Coverage On | → Overweight |
| 11/08/2021 | 1080.56% | Needham | → $17 | Initiates Coverage On | → Buy |
What is the target price for Lucid Diagnostics (LUCD)?
The latest price target for Lucid Diagnostics (NASDAQ: LUCD) was reported by Cantor Fitzgerald on August 22, 2023. The analyst firm set a price target for $4.00 expecting LUCD to rise to within 12 months (a possible 177.78% upside). 9 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lucid Diagnostics (LUCD)?
The latest analyst rating for Lucid Diagnostics (NASDAQ: LUCD) was provided by Cantor Fitzgerald, and Lucid Diagnostics reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Lucid Diagnostics (LUCD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lucid Diagnostics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lucid Diagnostics was filed on August 22, 2023 so you should expect the next rating to be made available sometime around August 22, 2024.
Is the Analyst Rating Lucid Diagnostics (LUCD) correct?
While ratings are subjective and will change, the latest Lucid Diagnostics (LUCD) rating was a reiterated with a price target of $0.00 to $4.00. The current price Lucid Diagnostics (LUCD) is trading at is $1.44, which is within the analyst's predicted range.